A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...

For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...